Predictive Oncology’s, Skyline Medical Division, Developing Generation 3 Direct-to-Drain Automated Fluid Waste Management S...
March 08 2021 - 8:30AM
Predictive Oncology (NASDAQ: POAI), a
knowledge-driven company focused on applying artificial
intelligence (“AI”) to personalized medicine and drug discovery,
announced today that its Skyline Medical Division is renewing
developing a new Generation 3 STREAMWAY ® System for
direct-to-drain fluid waste management. The new device will see no
change to its intended use and will not require a separate 501(k)
submission with the Food and Drug Administration.
Some of the key changes to the new generation
product will include a 25% size reduction, a portable wall mounting
plate to simplify installation thus reducing installation costs, an
automated dripless system that ensures optimal reliability
when changing out the filters between procedures, modularized
subassemblies which will streamline assembly and servicing, a new
drop down cover design that allows for access to the core of the
unit also for easier servicing, a new software providing state of
the art on screen graphics with the latest technology to allow for
on screen training as needed, a reduction in both electrical and
mechanical internal connections increasing vacuum efficiency,
eliminating relays and I/O’s (input/output) through a newly
developed integrated PC board providing for real time fluid waste
measurement. Lastly, this new design will be smaller, lighter,
easier to install with the goal of improving operator reliability,
reducing manufacturing costs, increasing durability and simplifying
servicing.
“Skyline Medical plans to follow shortly with a
Generation 3 Plus machine which includes an integrated on board
vacuum pump so the facility vacuum supply will not be required
or at the least can be augmented if needed,” commented Dr. Carl
Schwartz, CEO of Predictive Oncology.
About Predictive Oncology Inc.
Predictive Oncology (NASDAQ: POAI) operates through
three segments (Skyline, Helomics and Soluble Biotech), which
contain four subsidiaries: Helomics, TumorGenesis, Skyline Medical
and Soluble Biotech.
Helomics applies artificial intelligence to its
rich data gathered from patient tumors to both personalize cancer
therapies for patients and drive the development of new targeted
therapies in collaborations with pharmaceutical companies.
TumorGenesis Inc. specializes in media that help cancer cells grow
and retain their DNA/RNA and proteomic signatures, providing
researchers with a tool to expand and study cancer cell types found
in tumors of the blood and organ systems of all mammals, including
humans. Skyline Medical markets its patented and FDA cleared
STREAMWAY System, which automates the collection, measurement, and
disposal of waste fluid, including blood, irrigation fluid and
others, within a medical facility, through both domestic and
international divisions. Soluble Biotech is a provider of soluble
and stable formulations for proteins including vaccines,
antibodies, large and small proteins, and protein complexes.
Forward-Looking Statements
Certain matters discussed in this release contain
forward-looking statements. These forward-looking statements
reflect our current expectations and projections about future
events and are subject to substantial risks, uncertainties and
assumptions about our operations and the investments we make. All
statements, other than statements of historical facts, included in
this press release regarding our strategy, future operations,
future financial position, future revenue and financial
performance, projected costs, prospects, plans and objectives of
management are forward-looking statements. The words “anticipate,”
“believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “would,”
“target” and similar expressions are intended to identify forward-
looking statements, although not all forward-looking statements
contain these identifying words. Our actual future performance may
materially differ from that contemplated by the forward-looking
statements because of a variety of factors including, among other
things, factors discussed under the heading “Risk Factors” in our
filings with the SEC. Except as expressly required by law, the
Company disclaims any intent or obligation to update these
forward-looking statements.
Investor Relations Contact:
Landon Capital Keith Pinder (404)
995-6671kpinder@landoncapital.net
Predictive Oncology (NASDAQ:POAI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Predictive Oncology (NASDAQ:POAI)
Historical Stock Chart
From Apr 2023 to Apr 2024